Summarized by Masters of Longevity from Longevity Technology.
Eisai reported five-year clinical and real-world findings on lecanemab.
Key Takeaways
- Five-year data are reported on lecanemab clinical outcomes.
- Real-world studies are reported assessing lecanemab use and ARIA.
- Biomarker durability and stopping dosing were analyzed but remain unproven.
